The use of psychotropic medications in pregnancy and lactation

British Columbia Medical Journal

Volumn 47, Issue 3, 2005, Pages 135-138

  Sivertz, Kristin ^a,b   Kostaras, Xanthoula ^c  

^a Providence Health Care ^*  (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CHLORPROMAZINE; CLOMIPRAMINE; CLONAZEPAM; CLOZAPINE; DESIPRAMINE; DIAZEPAM; DOXEPIN; GABAPENTIN; HALOPERIDOL; IMIPRAMINE; LAMOTRIGINE; LITHIUM; LORAZEPAM; LOXAPINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TOPIRAMATE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; VALPROIC ACID; ZIPRASIDONE;

APNEA; BREAST FEEDING; CHILD DEVELOPMENT; CONGENITAL MALFORMATION; CYANOSIS; DELIVERY; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG INFORMATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG UTILIZATION; EBSTEIN ANOMALY; FETUS DISEASE; FETUS MALFORMATION; FIRST TRIMESTER PREGNANCY; HEALTH HAZARD; HUMAN; IRRITABILITY; LABOR; LACTATION; LETHARGY; LOW BIRTH WEIGHT; MENTAL DISEASE; MUSCLE HYPOTONIA; NEURAL TUBE DEFECT; NEUROTOXICITY; NEWBORN DISEASE; ORGANOGENESIS; PERINATAL DRUG EXPOSURE; PHARMACOEPIDEMIOLOGY; PREGNANCY; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PUERPERIUM; RESPIRATORY FAILURE; RESTLESSNESS; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SEIZURE; SIDE EFFECT; TERATOGENICITY; THIRD TRIMESTER PREGNANCY; THROMBOCYTOPENIA; WITHDRAWAL SYNDROME;

EID: 19344361993     PISSN: 00070556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Marchetti F, Romero M, Bonati M, et al. Use of psychotropic drugs during pregnancy. A report of the international cooperative drug use in pregnancy (DUP) study. Eur J Clin Pharmacol 1993;45:495-501.
2. Altshuler L, Cohen L, Szuba MP, et al. Pharmacologie management of psychiatric illness during pregnancy: Dilemmas and guidelines. Am J Psychiatry 1996;153:592-606.
3. McElhatton PR. The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol 1994;8:461-475.
4. Crombie DL, Pinsent RJ, Slater BC, et al. Teratogenic drugs - Royal College of General Practitioners Survey. BMJ 1970;4:178-179.
5. Kuenssberg EV, Knox JD. Teratogenic effect of anticonvulsants. Lancet 1973;1:198.
6. Wisner KL, Perel JM, Wheeler SB. Tricyclic dose requirements across pregnancy. Am J Psychiatry 1993;150:1541-1542.
7. Edlund MJ, Craig TJ. Antipsychotic drug use and birth defects: An epidemiological reassessment. Compr Psychiatry 1984;25:32-37.
8. Patton SW, Misri S, Corral MR, et al. Antipsychotic medication during pregnancy and lactation in women with schizophrenia: Evaluating the risk. Can J Psychiatry 2002;47:959-965.
9. Cohen LS, Friedman JM, Jefferson JW, et al. A re-evaluation of risk of in utero exposure to lithium. JAMA 1994;271:146-150.
10. Iqbal MM. The effects of valproic acid on fetuses, neonates, and nursing infants. Psychiatr Ann 2000;30:221-227.
11. Goldstein DJ, Corbin LA, Fung MC. Olanzapine exposed pregnancies and lactation: Early experience. J Clin Psychopharmacol 2000;20:399-403.
12. Barnas C, Bergant A, Hummer M, et al. Clozapine concentration in maternal and fetal plasma, amniotic fluid, and breast milk. Am J Psychiatry 1994;151:945.
13. Hale TW. Medications and Mothers' Milk. 9th ed. Amarillo, TX: Pharmasoft Medical Publishing; 2000.
14. Llewellyn A, Stowe ZN, Strader JR. The use of lithium and management of women with bipolar disorder during pregnancy and lactation. J Clin Psychiatry 1998;59(suppl 6):57-64.
15. Wisner KL, Perel JM. Serum levels of valproate and carbamazepine in breastfeeding mother-infant pairs. J Clin Psychopharmacol 1998;18:167-169.